DDInter1266 DDInter899
Naproxen is classified as a nonsteroidal anti-inflammatory dug (NSAID) and was initially approved for prescription use in 1976 and then for over-the-counter (OTC) use in 1994. It can effectively manage acute pain as well as pain related to rheumatic diseases, and has a well studied adverse effect profile. Given its overall tolerability and effectiveness, naproxen can be considered a first line treatment for a variety of clinical situations requiring analgesia. Naproxen is available in both immediate and delayed release formulations, in combination with sumatriptan to treat migraines, and in combination with esomeprazole to lower the risk of developing gastric ulcers.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Naproxen {u} (Compound) resembles {v} (Compound) Suprofen
Naproxen {u} (Compound) resembles {v} (Compound) Oxybenzone
Naproxen {u} (Compound) treats {v} (Disease) gout
Naproxen {u} (Compound) binds {v} (Gene) CYP2C9
Naproxen {u} (Compound) upregulates {v} (Gene) FAM63A
Naproxen {u} (Compound) palliates {v} (Disease) osteoarthritis
Naproxen {u} (Compound) is included by {v} (Pharmacologic Class) Nonsteroidal Anti-inflammatory Compounds
Naproxen {u} (Compound) downregulates {v} (Gene) TXLNA
Naproxen {u} (Compound) causes {v} (Side Effect) Muscular weakness
Naproxen {u} (Compound) binds {v} (Gene) and {u} (Compound) upregulates {v} (Gene) PTGS2
Naproxen (Compound) resembles Suprofen (Compound)
Naproxen (Compound) resembles Oxybenzone (Compound)
Naproxen (Compound) treats gout (Disease)
Naproxen (Compound) binds CYP2C9 (Gene)
Naproxen (Compound) upregulates FAM63A (Gene)
Naproxen (Compound) palliates osteoarthritis (Disease)
Naproxen (Compound) is included by Nonsteroidal Anti-inflammatory Compounds (Pharmacologic Class)
Naproxen (Compound) downregulates TXLNA (Gene)
Naproxen (Compound) causes Muscular weakness (Side Effect)
Naproxen (Compound) binds PTGS2 (Gene) and Naproxen (Compound) upregulates PTGS2 (Gene)